Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of ABBV-400 plus FOLFIRI + bevacizumab in previously treated unresectable metastatic colorectal cancer
jRCT2031230442Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial of telisotuzumab adizutecan in colorectal cancer (CRC), sponsored by AbbVie Inc. Primary endpoints: Objective response rate and Progression-free survival. Started Jan 2024; status: recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2031230442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230442.